Neupogen (Filgrastim)

Filgrastim, the active ingredient in Neupogen, is a granulocyte colony-stimulating factor presented as a 300 µg per vial injectable solution (lyophilized powder for reconstitution) for intravenous or subcutaneous use. It treats chemotherapy‑induced neutropenia, supports bone marrow transplantation, severe chronic neutropenia, and aids peripheral blood stem cell mobilization.

GNH USA supplies Neupogen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Neupogen (filgrastim) is a hematopoietic growth factor used to manage neutropenia and related conditions.

- Chemotherapy‑induced neutropenia: reduces duration of neutropenia and lowers infection risk in patients receiving cytotoxic chemotherapy. - Bone marrow transplantation: accelerates neutrophil recovery after high‑dose conditioning regimens. - Severe chronic neutropenia: increases absolute neutrophil count to reduce infection susceptibility. - Peripheral blood stem cell mobilization: enhances collection of CD34+ stem cells for autologous transplantation.

Neupogen may be associated with a range of adverse reactions, most of which are related to its pharmacologic activity or the injection process.

Common Side Effects: - Bone pain: discomfort in bones or joints, often mild to moderate. - Injection site reactions: redness, swelling, or tenderness at the administration site. - Fever: transient elevation of body temperature. - Headache: mild to moderate headache occurring shortly after dosing.

Serious or Rare Side Effects: - Splenic rupture: sudden abdominal pain and signs of internal bleeding. - Acute respiratory distress syndrome: severe breathing difficulty requiring urgent care. - Allergic reactions (anaphylaxis): hives, swelling, or airway compromise. - Capillary leak syndrome: rapid fluid shift leading to hypotension and edema.

Neupogen requires careful clinical monitoring and adherence to handling guidelines.

- Dose adjustment: individualize based on neutrophil counts and clinical response. - Renal impairment: monitor closely; no specific dose reduction is routinely recommended. - Spleen size: assess for splenomegaly; discontinue if splenic rupture is suspected. - Concurrent chemotherapy: coordinate timing to avoid overlapping toxicities. - Pregnancy and lactation: use only if potential benefit justifies potential risk; data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Neupogen can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Cytotoxic chemotherapy agents: inappropriate timing may increase myelosuppression. - Corticosteroids: may blunt the neutrophil response to filgrastim. - Other colony‑stimulating factors: additive effects on leukocytosis can occur.

Moderate Interactions (Monitor Closely): - Antibiotics (e.g., beta‑lactams): may mask signs of infection. - Immunosuppressants (e.g., cyclosporine): monitor for infection risk. - Live attenuated vaccines: reduced efficacy; avoid administration during filgrastim therapy.